Strides Arcolab Pharma, the drug firm on 25 June 2013 announced that it was given World Health Organisation (WHO) pre- qualification for the anti-malarial tablets which will be launched immediately. These tablets are called Artemether and Lumifantrine (AL) tablets.
The Artemether and Lumifantrine (AL) tablets consist of more than 80 percent artemesinin combination therapy (ACT), which is procured under Global Fund as well as similar programmes. This is said to be yet another initiative of Strides Arcolab Pharma for making affordable and high quality medicines which will be available in African sub-continent as well as other middle-income countries.
World Health Organisation (WHO) pre- qualification of medicines is actually the service which is provided by the WHO in order to assess safety, quality as well as efficacy of the medicinal products. It is very important to note that in the year 2002, Artemether and Lumefantrine tablets were included to the WHO’s list of Essential Medicines.
Artemether and Lumifantrine (AL) tablets of Strides Arcolab Pharma will be produced at the US Food and Drug Administration approved and WHO pre-qualified facility in Bengaluru.
There were more than 300 million new malaria cases detected in the year 2011 in Africa alone. With the approval of Artemether and Lumifantrine (AL) tablets, Strides Arcolab Pharma has become the only pharmaceutical company to offer complete treatment portfolio for diseases such as malaria, TB and HIV. These three are the major diseases which plague the middle-income as well as low income countries.
DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.